AE Wealth Management LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,225 shares of the biopharmaceutical company's stock after acquiring an additional 445 shares during the period. AE Wealth Management LLC's holdings in Regeneron Pharmaceuticals were worth $1,412,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Capital International Investors grew its holdings in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after acquiring an additional 1,390,534 shares during the period. Geode Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after buying an additional 155,369 shares during the last quarter. Dodge & Cox grew its stake in shares of Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after buying an additional 9,381 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after buying an additional 810,144 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in shares of Regeneron Pharmaceuticals by 7.9% in the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock worth $1,456,864,000 after buying an additional 149,124 shares during the last quarter. Institutional investors own 83.31% of the company's stock.
Wall Street Analysts Forecast Growth
REGN has been the topic of several analyst reports. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. The Goldman Sachs Group lowered their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Bank of America cut their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. Finally, BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research report on Monday, June 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $837.61.
View Our Latest Research Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Stock Down 0.1%
NASDAQ:REGN traded down $0.79 during midday trading on Thursday, hitting $553.79. 323,949 shares of the company were exchanged, compared to its average volume of 1,108,473. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $59.79 billion, a PE ratio of 14.05, a price-to-earnings-growth ratio of 2.09 and a beta of 0.33. The company has a fifty day simple moving average of $539.67 and a 200 day simple moving average of $606.17.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm's revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $9.55 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.
Regeneron Pharmaceuticals Company Profile
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Read More

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.